Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336842 · ClinicalTrials.gov registry record · Phase 1
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
A Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT01336842 is a Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that has completed, run by University of California, Davis. The registered enrollment target is 23 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01336842, a Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet chemotherapy alone.
Conditions Studied
Interventions
- DRUG Panobinostat, Cisplatin, Pemetrexed
Study Locations (2)
California
- University of California Davis Cancer Center - Sacramento
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336842
The ClinicalTrials.gov registry entry for NCT01336842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (92% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Panobinostat, Cisplatin, Pemetrexed is the first listed.
NCT01336842 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Michigan.
Frequently Asked Questions
What is clinical trial NCT01336842 about?
NCT01336842 is a clinical study titled "Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors". The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet chemotherapy alone.
What is the current status of trial NCT01336842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2011-04. Estimated completion is 2017-06.
What conditions does trial NCT01336842 study?
This clinical trial studies the following conditions: Solid Tumors, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT01336842?
The interventions under investigation include: Panobinostat, Cisplatin, Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT01336842?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01336842 being conducted?
This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.